Stockscreener 앱 받기
39.86
0.28%
-0.11
전일 마감가:
$39.97
열려 있는:
$39.55
하루 거래량:
423.38K
Relative Volume:
0.40
시가총액:
$3.85B
수익:
$225.27M
순이익/손실:
$-140.06M
주가수익비율:
-24.95
EPS:
-1.5974
순현금흐름:
$-87.93M
1주 성능:
-0.62%
1개월 성능:
+10.38%
6개월 성능:
+14.94%
1년 성능:
+54.32%
1일 변동 폭
$39.42
$40.07
1주일 범위
$38.90
$41.48
52주 변동 폭
$23.23
$42.68
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
39.86 | 3.77B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-09-04 | 개시 | Barclays | Overweight |
| 2025-09-04 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-22 | 개시 | TD Cowen | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-26 | 개시 | Wells Fargo | Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-11-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2024-03-08 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa
IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (IDYA) Cash Flow Statement - Moomoo
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
IDEAYA Biosciences (IDYA) Holds Near $37 as Bulls Eye Breakout Above $38.81 ResistanceVolume Breakout Ideas - Vinanet
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62 - Moomoo
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
How (IDYA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Strong Position To Grow Its Business - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Yahoo Finance
IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60 - Moomoo
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37 - Bitget
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend - stocktitan.net
IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M - marketscreener.com
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion | IDYA Stock News - Quiver Quantitative
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
IDEAYA Biosciences (IDYA) Stock Analysis: Unpacking a 51% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion - Quiver Quantitative
IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday - MarketBeat
Seven Fleet Capital Management LP Buys New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Vanguard Capital Management (IDYA) discloses 4.83M-share passive stake in Ideaya - Stock Titan
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLC - MarketBeat
SummitTX Capital L.P. Purchases New Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA initiates expansion phase for cancer drug IDE892 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - PR Newswire
IDEAYA expands cancer trial after IDE892 reaches target exposure - Stock Titan
IDEAYA Biosciences Inc (IDYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEAYA Biosciences Inc (IDYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IDEAYA Biosciences Inc (IDYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ideaya Biosciences Inc 주식 (IDYA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Sale |
40.01 |
9,550 |
382,131 |
26,466 |
0.86%
0.31%
자본화:
|
볼륨(24시간):